ArticleBMC molecular and cell biology2026
Investigating the roles of macrophage age and circulating extracellular vesicles in cytoprotection of hypoxic renal tubular cell stress.
Article in BMC molecular and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAcute kidney injury (AKI) involves complex crosstalk between tubular epithelial cells (TECs) and immune cells. Extracellular vesicles (EVs) and ageing have emerged as modulators of this process.
methodsWe investigated the effects of circulating plasma EVs from young (Y_EVs) and old (O_EVs) mice on hypoxic TEC stress, using bone marrow–derived macrophages (BMDMs) from young or old mice, which were pre-conditioned with EVs. First, direct effects of EVs on TEC viability were assessed following hypoxia/reoxygenation injury. We then examined macrophage responses to hypoxic TEC secretomes with or without EV priming, and tested whether EV-primed BMDM secretomes modulated TEC damage, in terms of viability, cytokine expression, and epithelial–mesenchymal transition (EMT).
resultsEVs exerted no direct protective effect on hypoxic TECs, and no significant differences were observed between Y_EVs and O_EVs in any condition. Instead, macrophage donor age was the most significant determinant of outcomes. Conditioned medium from old BMDMs consistently improved TEC viability compared to young BMDMs. In agreement with this, the old mouse BMDM secretome also suppressed hypoxia-induced cytokine expression (Il6, Ccl2) and EMT marker induction (Acta2, Fn1) in hypoxic TECs. EV pre-treatment of BMDMs did not significantly alter these effects in either macrophage group. Thus, BMDM donor age, rather than EV donor age, was the critical driver of cytoprotection and inflammatory modulation in this model.
conclusionCirculating plasma EV age had no significant direct or indirect impacts on TEC viability, inflammatory responses or EMT processes under the tested conditions. This contrasts with prior studies which have suggested broadly rejuvenating effects of young EVs and detrimental effects of old EVs. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.